Ken Griffin Cure Vac N.V. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cure Vac N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 21,400 shares of CVAC stock, worth $75,756. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,400
Previous 118,300
81.91%
Holding current value
$75,756
Previous $498,000
87.15%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CVAC
# of Institutions
95Shares Held
15.3MCall Options Held
31.4KPut Options Held
137K-
Israel Englander Millennium Management LLC | New York, Ny2.76MShares$9.77 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.97MShares$6.99 Million0.0% of portfolio
-
Camber Capital Management LP Boston, MA1.75MShares$6.2 Million0.13% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.6MShares$5.66 Million5.88% of portfolio
-
Morgan Stanley New York, NY844KShares$2.99 Million0.0% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $664M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...